AbClon KRX:174900KOSDAQ
앱클론 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days7
DART filings, 7 days1
Articles tracked8since Sep 11
In Q2 2026, AbClon reported revenue of ₩1.7bn, up 51.4% year on year, and an operating loss of ₩6.3bn. AbClon (앱클론) appeared in 7 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 29 with 7 articles. The most common catalyst was contracts & orders (2). It was most often mentioned alongside HLB Pharmaceutical.
Filing signals Supply contract 4 quarters of losses Screener
AbClon quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.7bn | +51.4% | −₩6.3bn | −₩6.1bn |
| Q1 2026 | ₩434m | +5.2% | −₩3.1bn | −₩2.8bn |
| Q4 2025 derived | ₩1.6bn | +128.6% | −₩5.0bn | −₩5.1bn |
| Q3 2025 | ₩1.6bn | +96.3% | −₩3.5bn margin −225.9% | −₩3.5bn |
| Q2 2025 | ₩1.1bn | +181.8% | −₩3.3bn | −₩3.5bn |
| Q1 2025 | ₩413m | -5.6% | −₩5.8bn | −₩6.0bn |
| Q4 2024 derived | ₩710m | +26.0% | −₩3.2bn | −₩3.3bn |
| Q3 2024 | ₩798m | +18.0% | −₩3.3bn | −₩3.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
AbClon top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest AbClon news Korean headlines
-
앱클론 AC101, 中 결직장암 2상 확대…임상 9건으로
1 more on this story · 1 outlets
- 앱클론 ‘AC101’ 임상 9건으로 확대…결직장암·ADC 치료 후 유방암 추가PRESS9 · Sep 29 10:00